SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical data from its AI driven drug discovery programs. The company highlighted progress in oncology and rare disease candidates in ...
The artificial intelligence (AI) revolution continues to tout developing drugs faster and at lower cost, but are we there yet? On October 2nd, the FDA cleared an investigational new drug (IND) ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results